来那度胺治疗多发性骨髓瘤的临床疗效及其安全性  

Clinical efficacy and safety of lenalidomide in the treatment of multiple myeloma

作　　者：江炜 罗萍[1] JIANG Wei;LUO Ping(Department of Hematology,the First People's Hospital of Jiujiang City,Jiujiang 332000,China)

机构地区：[1]江西省九江市第一人民医院血液内科,332000

出　　处：《临床合理用药杂志》2021年第21期30-32,共3页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的探讨来那度胺治疗多发性骨髓瘤(MM)中的临床疗效及其安全性。方法选取九江市第一人民医院2017年1月—2020年6月收治的MM患者90例,采用随机数字表法分为来那度胺组、沙利度胺组,每组45例。来那度胺组采用VRD方案(硼替佐米、来那度胺与地塞米松)治疗,沙利度胺组给予VTD方案(硼替佐米、沙利度胺与地塞米松)治疗。比较2组临床疗效,治疗前后血清β2-微球蛋白、M蛋白水平,毒副作用发生情况。结果来那度胺组治疗总有效率高于沙利度胺组(P<0.05)。治疗前2组血清β2-微球蛋白、M蛋白水平比较,差异无统计学意义(P>0.05);治疗后来那度胺组血清β2-微球蛋白、M蛋白水平低于沙利度胺组(P<0.05)。来那度胺组毒副作用发生率低于沙利度胺组(P<0.05)。结论来那度胺治疗MM中的临床疗效确切,可提高免疫能力,且安全性较高。Objective To investigate the clinical efficacy and safety of lenalidomide in the treatment of multiple myeloma(MM).Methods A total of 90 cases of MM patients were selected from January 2017 to June 2020 in the First People's Hospital of Jiujiang City,which were divided into lenalidomide group and thalidomide group according to random number table,45 cases in each group.The lenalidomide group was treated with VRD(bortezomib,lenalidomide and dexamethasone),and the thalidomide group was treated with VTD(bortezomib,thalidomide and dexamethasone).The clinical efficacy,the serum levels ofβ2-microglobulin and M-protein before and after treatment were compared between the two groups,and the occurrence of adverse reactions.Results The total effective rate of lenalidomide group was higher than that of thalidomide group(P<0.05).Before treatment,the serum levels ofβ2-microglobulin and M-protein were no significant difference between the two groups(P>0.05);after treatment,the serum levels ofβ2-microglobulin and M-protein of the naduramide group were lower than those in thalidomide group(P<0.05).The incidence of adverse reactions in lenalidomide group was lower than that in thalidomide group(P<0.05).Conclusion Lenalidomide in the treatment of MM has definite clinical effect,can improve the immune ability,and with high safety.

关 键 词：多发性骨髓瘤 来那度胺 治疗结果 安全性 

分 类 号：R733.3[医药卫生—肿瘤]